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Gregory L. Moneta, MD, Section EditorStatin Use and Rupture of Abdominal Aortic Aneurysm
Wemmelund H, Høgh A, Hundborg HH, et al. Br J Surg 2014;101:966-75.
Conclusions: Statin use is associated with a reduced risk of rupture of
abdominal aortic aneurysm (AAA) and lower case fatality following rupture
of AAA.
Summary: There have been studies suggesting that statins may
reduce AAA growth rates and rupture risk by enhancing endothelial func-
tion and attenuating oxidative stress and inﬂammation of the vessel wall
(Liao JK. Am J Cardiol 2005;96: 24F-33F). Meta-analyses also suggests
decreased growth rate of AAAs with the use of statins (Sweeting MJ et al,
Br J Surg 2012;99:655-65). In addition there have been small, single-center
observational studies suggesting an association between prehospital statin
therapy and lower mortality following surgery for ruptured (rAAA) (Feeney
JM et al, J Am Coll Surg 2009;209:41-6). In the current study the authors
use the Danish National Registry of Patients, to examine incident rAAA
cases and AAA control patients with a focus on the risk and prognosis of
rAAA. This was a nationwide, population-based, combined case-control
and follow-up study that included all patients (aged at least 50 years) with
a ﬁrst-time hospital admission for rAAA and 1:1 matched AAA controls
without rupture in Denmark, from 1996 to 2008. Individual-level data
on preadmission drug use, co-morbidities, socioeconomic markers, health
care contacts and death were obtained from nationwide registries. The study
included 3584 cases and 3584 match controls. Current statin use was regis-
tered for 418 patients with rAAA (11.7%) and 539 AAA controls (15.0%),
corresponding to an age- and sex-matched odds ratio of 0.7 (95% conﬁ-
dence interval [CI], 0.60-0.81) for rAAA in current statin users vs never
users. The decreased risk of rAAA remained after adjustment for potential
confounding factors (adjusted odds ratio, 0.73; 95% CI, 0.61-0.86). Over-
all, 30-day mortality rate from time of hospital admission among patients
with rAAA was 46.1% in current statin users compared with 59.3% in never
users (adjusted mortality rate [MRR] 0.80; 95% CI, 0.68-0.95). Patients
who had formerly used statins did not have reduced mortality (adjusted
MRR, 0.98; 95% CI, 0.78-1.22).
Comment: The study suggests beneﬁts for statins in patients with
AAA both in lower rupture rates and improved survival of ruptures. How-
ever, it has a number of signiﬁcant limitations in that there was no data
on AAA diameter, a known predictor of rupture. It may also be possible
that patients who use statins are more cooperative in adherence to medical
recommendations and have greater contact with a health care system, and
therefore they are perhaps more healthy overall. Such patients may have
their aneurysms diagnosed at a smaller size prior to rupture where they
can be repaired electively. Nevertheless, given that patients with AAA gener-
ally have manifestations of atherosclerosis and vascular disease other than
AAA that beneﬁt from statins, there seems to be no downside to placing pa-
tients with AAAs on a statin medication. Certainly additional analyses of
possible mechanisms of beneﬁt are needed, but for the moment the results
of this study support current guidelines that recommend initiation of pro-
phylactic statin treatment in asymptomatic patients with AAA (Chaikof
EL et al, J Vasc Surg 2009;50(Suppl):S2-S49), and (Moll FL, Eur J Vasc
Endovasc Surg 2011;41(Suppl 1):S1-S58).
Outcomes After Endovascular or Open Repair for Degenerative
Descending Thoracic Aortic Aneurysm Using Linked Hospital Data
von Allmen RS, Anjum A, Powell JT. Br J Surg 2014;101:1244-51.
Conclusions: In England, mortality for treatment of degenerative
descending thoracic aneurysm is similar with open repair and TEVAR. Pa-
tients treated with TEVAR however higher re-intervention rates and worse
long-term survival.
Summary: Degenerative thoracic aortic aneurysms are now preferen-
tially treated with TEVAR instead of open repair by many surgeons. Com-
parisons however between TEVAR and open repair of degenerative thoracic
aortic aneurysms have generally been through the use of registries, and in
the U.S. a large Medicare database. The Medicare study determined 30-
day and 5-year survival for an elective and emergency repair of descendingthoracic aortic aneurysms between 1998 and 2007. Although mortality was
lower for TEVAR than open repair 6.1% vs 7.1%; this did not reach statis-
tical signiﬁcance. In addition, 5-year survival was worse after TEVAR
(73% vs 81%). This study however was conducted when TEVAR was under-
going fairly rapid technological change and to date updated reports were
not available (Goodney PP et al, Circulation 2011;124:2661-9). In this
study the authors analyzed patients aged over 50 years without a history
of aortic dissection, who underwent repair of a thoracic aortic aneurysm be-
tween 2006 and 2011, a more recent cohort than the Medicare study. Prin-
ciple outcomes were 30-day operative mortality, long-term survival
(5 years), and aortic-related reinterventions. TEVAR and open repair
were compared using mortality linked individual patient data from hospital
episodes statistics (England) with crude and multivariable models and
adjusted for age and sex. There were 759 patients who underwent thoracic
aortic aneurysm repair, mainly for intact aneurysms (n ¼ 618; 81.4%). Me-
dian ages of TEVAR and open cohorts were 73 and 71 years respectively (P
< .001). More men than women underwent TEVAR (P ¼ .004). For intact
aneurysms operative mortality rate was similar for TEVAR and open repair
(6.5% vs 7.6%; odds ratio, 0.79; 95% CI, 0.41-1.49). 5-year survival rate
however was signiﬁcantly worse after TEVAR (54.2% vs 65.6%; adjusted
hazard ratio [HR], 1.45; 95% CI, 1.08-1.94). After 5 years, aortic-related
mortality was similar in the two groups, but cardiopulmonary mortality
was higher after TEVAR. TEVAR was associated with more aortic-related
re-interventions (23.1% vs 14.3%; adjusted HR, 1.70, 95% CI, 1.11-
2.60). There were 141 procedures for ruptured thoracic aneurysm (97
TEVAR, 44 open) with TEVAR showing no signiﬁcant advantage in terms
of operative mortality.
Comment: It is certainly possible that selection bias and increased car-
diopulmonary morbidity may contribute to the decreased long-term survival
of patients treated with TEVAR vs open repair for thoracic aortic aneurysm.
Anecdotally, many surgeons feel patients with thoracic aneurysms have
increased comorbidities vs those with abdominal aortic aneurysms and
therefore ﬁnd TEVAR an attractive alternative to open repair reﬂected in
the increasing numbers of thoracic aneurysms treated with endovascular
techniques. However, we still don’t know whether the technique is cost-
effective and truly effective. Clearly TVAR can be costly, especially if one
considers the increase expense of surveillance and aortic related reinterven-
tions. The authors contend that based on the available data and lack of cost-
effectiveness data a shift to elective endovascular treatment of descending
thoracic aortic aneurysms is not justiﬁed.
A Randomized Trial Comparing Treatments for Varicose Veins
Brittenden J, Cotton SC, Elders A, et al. N Engl J Med 2014;371:1218-27.
Conclusions: In a comparison of ultrasound-guided foam sclerother-
apy, endovenous laser ablation and surgical treatment for treatment of vari-
cose veins, all treatments had similar clinical efﬁcacy. Complications were
less frequent after laser treatment and ablation rates lower after foam
treatment.
Summary: Endovenous thermal ablation techniques and ultrasound
guided foam sclerotherapy are widely employed alternatives to surgery
for the treatment of varicose veins. Smaller randomized trials and meta-an-
alyses have concluded these treatments can be effective in terms of short-
term technical success in clinician reported outcomes. However, despite
the fact clinical practice guidelines recommend use of patient reported
quality of life to assess outcomes of procedures for varicose veins, quality
of life has never been the primary outcome measure in any randomized tri-
als involving treatment foam sclerotherapy. The authors therefore per-
formed a comparison of laser, surgery and foam sclerotherapy (CLASS)
trial to assess the relative efﬁcacies of these treatments in patients with pri-
mary varicose veins. This was a randomized trial involving 798 participants
with primary varicose veins at 11 centers in the United Kingdom. Out-
comes of foam, laser and surgical treatments were compared at 6 months
with disease-speciﬁc quality of life and generic quality of life questionnaires
as measured on several scales. Secondary outcomes included complications
and measures of clinical success. After adjustment for baseline scores and1709
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worse after treatment with foam than after surgery (P ¼ .006) but was
similar in the laser and surgery groups. There were no signiﬁcant differences
between the surgery group and the foam or laser group in measures of
generic quality of life. The frequency of procedural complications was
similar in the foam group (6%) and the surgery group (7%) but was lower
in the laser group (1%) than in the surgery group (P < .001). The frequency
of serious adverse events was approximately 3% and was similar among the
groups. Measures of clinical success were also similar among the groups, but
successful ablation of the main trunks of the saphenous vein was less com-
mon in the foam group than in the surgery group (P < .001).
Comment: The three groups had similar improvements in venous
clinical severity score at 6 months, however ablation of the great saphenous
vein at 6 weeks occurred signiﬁcantly less often after foam treatment (com-
plete ablation 55%; partial ablation with a patent segment and no reﬂux
23%) than after either surgery (compete ablation 84%; partial ablation 6%)
or laser treatment (complete ablation 83%; partial ablation 8%). Long-
term follow-up therefore will be required to determine the durability of
these treatments and the frequency of patients seeking retreatment after
each of these forms of therapy of primary varicose veins. See also Abstract 5,
“Patient-Reported Outcomes 5-8 Years After Ultrasound-Guided Foam
Sclerotherapy for Varicose Veins” in this issue of the Journal.
Retrograde Aortic Dissection After Thoracic Endovascular Aortic
Repair
Canaud L, Ozdemir BA, Patterson BO, et al. Ann Surg 2014;260:389-95.
Conclusions: Retrograde type A aortic dissection (RTAD) after
TEVAR is an uncommon complication, but with a high mortality rate. It
occurs more frequently in patients treated for acute and chronic type B
dissection, and when the endograft is signiﬁcantly oversized.
Summary: Thoracic endovascular aortic repair (TEVAR) is utilized
for treatment of a wide variety of thoracic aortic pathologies. A potential le-
thal complication of this procedure is RTAD. So far, data with respect to
etiologic factors associated with RTAD are few and hampered by data qual-
ity and reporting parameters. The European Registry of Endovascular
Aortic Repair Complications reported 63 cases of RTAD among 4750
TEVAR procedures (Eggebrecht H et al, Circulation 2009;120:276-81).
While there’s a general consensus that RTAD may be more common in pa-
tients with acute type B aortic dissection there has been no deﬁnitive proven
association. In this study the authors sought to provide insight into the etio-
logical and procedural factors associated with RTAD following TEVAR.
Data were obtained from the MOTHER Registry (Patterson B et al, Circu-
lation 2013;127:24-32). These data were supplemented by cases from a sys-
tematic review of literature and data from both sources aggregated to report
the contemporary literature. Univariate analysis and binary logistic regres-
sion analysis of patient and technical factors was performed. In MOTHER,
RTAD developed in 16 of the 1010 patients (1.6%). Binary logistic regres-
sion demonstrated that an indication of TEVAR for aortic dissection (acute,
P ¼ .000212; chronic, P ¼ .006) and device oversizing (odds ratio, 1.14 per
1% increase in oversizing above 9%; P < .0001) were signiﬁcantly more
frequent in patients with RTAD. Data from the systematic review was
pooled with the MOTHER data and demonstrated that RTAD occurred
in 1.7% (168/9894). Most of RTAD occurred in the immediate postoper-
ative period (58%). Mortality rate was high at 33.6%. Odds ratio for RTAD
acute aortic dissection was 10.0 (95% conﬁdence interval, 4.7-21.9) and 3.4
(95% conﬁdence interval, 1.3-8.8) for chronic aortic dissection. Incidence of
RTAD was not signiﬁcantly different for endografts with a proximal bare
metal stent (2.8%) or a nonbare stent (1.9%; P ¼ .1298).
Comment: The majority of RTADs in this study occurred interopera-
tively (20.9%) or in the immediate postoperative period (50%). However,
29.1% suffered RTADmore than 30 days after the procedure. This combined
with the association with aortic endograft oversizing suggests that the
complication is likely related to a combination of natural progression of the
disease and fragility of the dissected aorta. Further studies should focus on
at what point after the occurrence of acute aortic dissection that the risk of
RTAD approaches that of treatment of a chronic aortic dissection and what
degree of aortic endograft oversizing is optimal to lower the risk of RTAD.
Patient-Reported Outcomes 5-8 Years After Ultrasound-Guided Foam
Sclerotherapy for Varicose Veins
Darvall KA, Bate GR, Bradbury AW. Br J Surg 2014;101:1098-104.
Conclusions: Ultrasound-guided foam sclerotherapy has durable results
as reported by patient-reported outcomes to at least 5 years. Only 15.3% of
limbs treated underwent retreatment for reoccurrence during follow-up.Summary: Treatment of varicose veins results in signiﬁcant improve-
ments in health-related quality of life (Baker DM et al, Eur J Vasc Endovasc
Surg 1995;9:299-304, and Michaels J et al, Br J Surg 2006;93:175-81). In
the UK the National Institute for Health and Care Excellence (NICE) vari-
cose vein clinical guideline published in July 2013 recommends patients
with symptomatic varicose veins, regardless of CEAP class, be referred for
assessment with duplex ultrasound imaging and consideration of interven-
tion, preferably by endovascular techniques (NICE guideline CG168, Lon-
don; 2013). However, to date few long-term data have been published on
venous interventions; with most existing reports continuing to focus on
technical outcomes rather than patient-reported outcome measures. Ultra-
sound-guided foam sclerotherapy (UGFS) has been reported to be clinically
effective with low rates of re-intervention in some studies but other studies
have raised concern that UGFS may not be as durable as surgery or endo-
thermal techniques. In this study the authors sought to investigate long-
term (5-8 years) outcomes following UGFS focusing on retreatment and
disease speciﬁc and generic health-related quality of life parameters, symp-
tom improvement, and meetings of patient expectations and overall patient
satisfaction. The study utilized consecutive patients undergoing UGFS be-
tween April 2004 and May 2007. Patients were invited for review at least
5 years after treatment. Patients completed generic (Short Form 12) and
disease-speciﬁc (Aberdeen Varicose Vein Symptom Severity Score, AVSS)
health-related quality of life questionnaires and questionnaires inquiring
about lower extremity symptoms, lifestyle factors, and satisfaction with
treatment. Data on retreatment was recorded prospectively. There were a
total of 391 limbs and 285 patients included (81.2% response rate) and a
median of 71 (interquartile range, 67-78) months following ﬁrst UGFS
treatment. Originally 72.1% had symptomatic uncomplicated varicose veins
while 21.9% had undergone previous surgery, and 82.7% had treatment of
great saphenous veins and 19.9% had treatment of the short saphenous
veins. Disease-speciﬁc health-related quality of life scores improved signiﬁ-
cantly at long-term follow-up, with 88.5% having an improved AVSS
compared with baseline. With respect to lower limb symptoms and lifestyle
improvement 62.7-93.8 per cent of patients had their pretreatment expec-
tations met or exceeded. 82% overall were very satisﬁed with their treat-
ments and only 3.3% were dissatisﬁed. 91% would recommend the
treatment to others. Kaplan-Meier analysis indicated 15.3% of limbs
required retreatment by 5 years.
Comment: In a recent systematic review the authors concluded that
endovenous laser treatment radio frequency ablation and UGFS and surgery
provided similar clinical outcomes in terms of reoccurrence, venous clinical
severity scores, short-term pain and quality of life (Carroll C et al, Health
Technol Assess 2013; 17 i-xvi, 1-141). The authors of the study point
out that this ﬁnding compared with general lower overall costs of UGFS
compared to endovenous thermal techniques and surgery suggest that
UGFS may be the most cost-effective option for treatment of varicose veins.
See also Abstract 3, “A Randomized Trial Comparing Treatments for Vari-
cose Veins” in this issue of the Journal.
Activities of Daily Living Is a Critical Factor in Predicting Outcome
After Carotid Endarterectomy in Asymptomatic Patients
Dayama A, Pimple P, Badrinathan B, et al. Stroke 2014;45:1703-8.
Conclusions: A patient’s inability to perform basic activities of inde-
pendent living is associated with adverse postoperative outcomes after ca-
rotid endarterectomy (CEA) for asymptomatic lesions.
Summary: The randomized trials of carotid endarterectomy both in
North America and Europe assessing the efﬁcacies of CEA for asymptomatic
disease generally excluded patients with a number of comorbid medical con-
ditions such as congestive heart failure, unstable angina, uncontrolled atrial
ﬁbrillation, or uncontrolled diabetes, etc. However, speciﬁc measures of
functional status were not utilized in patient stratiﬁcation in these trials.
The authors point out therefore that conventional models of stroke preven-
tion after CEA in asymptomatic patients have not been developed to accu-
rately predict outcomes in patients who are unable to perform activities of
daily living (Bekelis K et al, Stroke 2013;44: 1085-90). In this current study
the authors sought to assess the effect of preoperative functional status on
postoperative outcomes following CEA in asymptomatic patients. The hy-
pothesis was that preoperative functional disability would be associated
with worsened postoperative outcomes and in turn impaired survival of
the patients. Aided from the National Surgical Quality Improvement Proj-
ect, a national data set including data from more than 300 hospitals was uti-
lized in this study. Patients were identiﬁed by Current Procedural
Terminology (CPT) codes and divided into three categories based on func-
tional status; independent, partially dependent and dependent. Thirty-day
postoperative stroke, death and other postoperative complications were
identiﬁed as the study endpoint. Multivariate logistic regression analysis
